The choice among Delivery Methods for Hormone Replacement Therapy significantly influences efficacy, safety profile, and patient compliance. Oral tablets, the traditional route, are effective but carry a greater risk of venous thromboembolism (VTE) and stroke because they undergo a "first-pass" effect in the liver, increasing the production of clotting factors. Despite this risk, oral delivery remains a dominant segment due to its low cost and ease of use.

Transdermal options, including patches, gels, and sprays, have gained substantial clinical preference because they bypass the liver, reducing the risk of VTE and stroke, making them the safer choice for many women. Furthermore, vaginal rings, creams, and tablets are highly effective localized treatments for Genitourinary Syndrome of Menopause (GSM), delivering low doses of estrogen directly to the affected tissues without significant systemic absorption. The personalized tailoring of delivery based on symptom profile and risk factors is paramount in this therapeutic space.

Related Reports